SG11201605532YA - Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition - Google Patents

Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Info

Publication number
SG11201605532YA
SG11201605532YA SG11201605532YA SG11201605532YA SG11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA SG 11201605532Y A SG11201605532Y A SG 11201605532YA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
castor oil
acid compound
polyoxyethylene castor
containing pharmaceutical
Prior art date
Application number
SG11201605532YA
Other languages
English (en)
Inventor
Yoko Endo
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201605532YA publication Critical patent/SG11201605532YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201605532YA 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition SG11201605532YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Publications (1)

Publication Number Publication Date
SG11201605532YA true SG11201605532YA (en) 2016-08-30

Family

ID=53523959

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605532YA SG11201605532YA (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Country Status (19)

Country Link
US (3) US20160317512A1 (es)
EP (2) EP3093021B1 (es)
JP (5) JP6012775B2 (es)
KR (5) KR102230683B1 (es)
CN (2) CN110251516B (es)
AU (1) AU2015205268B2 (es)
BR (1) BR112016015911B1 (es)
CA (1) CA2934612C (es)
EA (1) EA031723B1 (es)
ES (2) ES2953346T3 (es)
GE (1) GEP20186916B (es)
HK (1) HK1224191A1 (es)
IL (1) IL246654B (es)
MX (1) MX2016009058A (es)
MY (1) MY166210A (es)
PH (1) PH12016501327B1 (es)
SG (1) SG11201605532YA (es)
TW (1) TWI612960B (es)
WO (1) WO2015105134A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205268B2 (en) * 2014-01-10 2019-03-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
ES2875307T3 (es) 2014-01-10 2021-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto derivado del ácido piridilaminoacético
CN105899209B (zh) 2014-01-10 2018-09-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
US20180200239A1 (en) 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
US10940144B2 (en) 2017-09-29 2021-03-09 Santen Pharmaceutical Co., Ltd. Drug containing pyridylaminoacetic acid compound
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination
TW201929854A (zh) 2017-12-28 2019-08-01 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥製劑
JP7217364B2 (ja) * 2019-11-29 2023-02-02 千寿製薬株式会社 医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP1011728B1 (en) * 1998-07-14 2004-12-29 Alcon Manufacturing, Ltd. Polypropylene containers for prostaglandin products
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
PT2264009T (pt) * 2008-03-12 2019-04-29 Ube Industries Composto do ácido piridilaminoacético
ES2564010T3 (es) * 2009-03-30 2016-03-17 Ube Industries, Ltd. Composición farmacéutica para tratar o prevenir el glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
AU2015205268B2 (en) * 2014-01-10 2019-03-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
CN105899209B (zh) * 2014-01-10 2018-09-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
ES2875307T3 (es) * 2014-01-10 2021-11-10 Santen Pharmaceutical Co Ltd Composición farmacéutica que contiene un compuesto derivado del ácido piridilaminoacético

Also Published As

Publication number Publication date
EA201691139A1 (ru) 2017-02-28
EP3093021B1 (en) 2021-06-02
US20230372316A1 (en) 2023-11-23
CA2934612A1 (en) 2015-07-16
EP3888654A1 (en) 2021-10-06
EA031723B1 (ru) 2019-02-28
US20200113880A1 (en) 2020-04-16
KR20160100977A (ko) 2016-08-24
JP2017031177A (ja) 2017-02-09
JP6793172B2 (ja) 2020-12-02
KR20210032547A (ko) 2021-03-24
JP6449205B2 (ja) 2019-01-09
AU2015205268A1 (en) 2016-07-14
MX2016009058A (es) 2016-09-09
NZ721530A (en) 2021-03-26
JP6012775B2 (ja) 2016-10-25
BR112016015911A2 (es) 2017-08-08
JP2015147762A (ja) 2015-08-20
CN110251516B (zh) 2022-05-03
US20160317512A1 (en) 2016-11-03
CN105828817A (zh) 2016-08-03
EP3888654B1 (en) 2023-06-14
IL246654B (en) 2020-05-31
GEP20186916B (en) 2018-11-12
PH12016501327A1 (en) 2017-02-06
TWI612960B (zh) 2018-02-01
IL246654A0 (en) 2016-08-31
KR20220146691A (ko) 2022-11-01
ES2874547T3 (es) 2021-11-05
CN110251516A (zh) 2019-09-20
ES2953346T3 (es) 2023-11-10
JP2021011508A (ja) 2021-02-04
KR102111157B1 (ko) 2020-05-14
CN105828817B (zh) 2019-07-05
KR102458180B1 (ko) 2022-10-21
CA2934612C (en) 2021-09-07
AU2015205268B2 (en) 2019-03-14
JP2019034973A (ja) 2019-03-07
BR112016015911B1 (pt) 2022-04-05
KR20200053651A (ko) 2020-05-18
TW201611833A (en) 2016-04-01
EP3093021A1 (en) 2016-11-16
KR20180050770A (ko) 2018-05-15
HK1224191A1 (zh) 2017-08-18
KR102230683B1 (ko) 2021-03-19
KR101858373B1 (ko) 2018-05-15
JP2022189964A (ja) 2022-12-22
MY166210A (en) 2018-06-22
EP3093021A4 (en) 2017-07-26
PH12016501327B1 (en) 2017-02-06
JP7170020B2 (ja) 2022-11-11
WO2015105134A1 (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
HK1224191A1 (zh) 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的藥物組合物
IL252477A0 (en) 2-aminopyrimidine compound, pharmaceutical structure and its use
IL253123A0 (en) Preparations for administration through the skin and their uses
HK1225655A1 (zh) 包含azd9291的藥用組合物
EP3102200A4 (en) Therapeutic compounds and compositions
IL246447A0 (en) A pharmaceutical preparation containing a pyridylaminoacetic acid compound
IL246655A0 (en) A medical preparation containing a pyridyl amino acetic acid compound
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
EP3102585A4 (en) Boronic acid esters and pharmaceutical formulations thereof
EP3149099A4 (en) Synthetic acid compositions and uses thereof
ZA201703398B (en) Pharmaceutical composition and methods
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
EP3139741A4 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
IL250729A0 (en) A pyrazolothiazole compound and a drug containing it
PL3184492T3 (pl) Preparat antyseptyczny
GB201417589D0 (en) Pharmaceutical Formulations
SG11201700122TA (en) Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same